Josef S Smolen

Medical University of Vienna — Austria

Medicine · Health Sciences

87h-index37.4kcitations533works14.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(305), Systemic Lupus Erythematosus Research(140), Autoimmune and Inflammatory Disorders Research(102), Monoclonal and Polyclonal Antibodies Research(70), Spondyloarthritis Studies and Treatments(65)

Publications531 total

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
Arthritis Research & Therapy·2025Open Access
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints (DAPSA44)
Annals of the Rheumatic Diseases·2025· 1 citedOpen Access
Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis
Annals of the Rheumatic Diseases·2025
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis
Clinical Drug Investigation·2025· 2 citedOpen Access
Certolizumab Inhibits Radiographic Progression Even in Rheumatoid Arthritis Patients with High Rheumatoid Factor Levels: A Pooled, Post Hoc Analysis of Two Phase 3 Trials
The Journal of Rheumatology·2025Open Access
Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis
Arthritis & Rheumatology·2025· 8 citedOpen Access
Greetings from the editor 2025/2
Annals of the Rheumatic Diseases·2025
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study
RMD Open·2025· 3 citedOpen Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Annals of the Rheumatic Diseases·2025· 16 citedOpen Access
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement
Annals of the Rheumatic Diseases·2025· 13 citedOpen Access
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
Annals of the Rheumatic Diseases·2025· 9 citedOpen Access
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study
Expert Review of Clinical Immunology·2025· 3 cited
Poor prognostic factors and unmet needs in rheumatoid arthritis
Lara D. Veeken·2025· 4 citedOpen Access
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study
Lara D. Veeken·2025· 1 citedOpen Access
Greetings from the Editor – 2025
Annals of the Rheumatic Diseases·2025
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
The Journal of Rheumatology·2024· 3 citedOpen Access
Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data
Current Medical Research and Opinion·2024· 2 citedOpen Access
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study
The Journal of Clinical Pharmacology·2024· 3 citedOpen Access
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47
RMD Open·2024· 7 citedOpen Access
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Lara D. Veeken·2024· 12 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Désirée van der Heijde(15), Daniel Aletaha(14), Robert Landewé(13), Paul Emery(12), Kurt Redlich(12), Gerd R Burmester(11), Georg Schett(11), Maxime Dougados(8), Laure Gossec(8), Kevin Winthrop(8), G Steiner(8), Iain B. McInnes(7), Maarten de Wit(7), Jochen Zwerina(7), Andreas Kerschbaumer(6), Tsutomu Takeuchi(6), Tore K Kvien(6), J. W. J. Bijlsma(5), Peter Nash(5), Xenofon Baraliakos(5)